This Article Full Text (Online First [PDF]) Related Article All Versions of this Article: 1940-6207.CAPR-08-0049v1 1/1/9    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Sporn, M. B. Articles by Hong, W. K. PubMed Articles by Sporn, M. B. Articles by Hong, W. K. Related Collections Perspective Key Article

Clinical Prevention of Recurrence of Colorectal Adenomas by the Combination of Difluoromethylornithine and Sulindac: An Important Milestone

Authors' Affiliations: ¹ Department of Pharmacology, Dartmouth Medical School, Hanover, New Hamsphire, and ² Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Michael B. Sporn, Department of Pharmacology, Dartmouth Medical School, 7650 Remsen, Hanover, NH 03755. Phone: 603-650-6557; Fax: 603-650-1129; E-mail: michael.sporn{at}dartmouth.edu.

Abstract

The spectacular clinical results reported by Meyskens, Gerner and colleagues in a lead article (1) of this very first issue of this new AACR journal on cancer prevention represent a landmark advance in efforts to stop the current worldwide epidemic of cancer deaths. This study also sets a new, exceptionally high standard for future clinical research on the chemoprevention of cancer.

Key Article

Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial

Frank L. Meyskens, Jr., Christine E. McLaren, Daniel Pelot, Sharon Fujikawa-Brooks, Philip M. Carpenter, Ernest Hawk, Gary Kelloff, Michael J. Lawson, Jayashri Kidao, John McCracken, C. Gregory Albers, Dennis J. Ahnen, D. Kim Turgeon, Steven Goldschmid, Peter Lance, Curt H. Hagedorn, Daniel L. Gillen, and Eugene W. Gerner
Cancer Prevention Research 2008 1: 32-38. [Abstract] [Full Text] [PDF]